AllianceBernstein
NKTR icon

AllianceBernstein’s Nektar Therapeutics NKTR Stock Holding History

AllianceBernstein’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,280
Closed -$33.5K – 3294
2025
Q1 		$33.5K Hold
3,280
– – ﹤0.01% 3162
2024
Q4 		$45.8K Hold
3,280
– – ﹤0.01% 3190
2024
Q3 		$64K Hold
3,280
– – ﹤0.01% 3173
2024
Q2 		$61K Buy
+3,280
New +$69.1K ﹤0.01% 3175
2023
Q2 		– Sell
-14,157
Closed -$149K – 3216
2023
Q1 		$149K Sell
14,157
-17,460
-55% -$528K ﹤0.01% 2970
2022
Q4 		$1.07M Sell
31,617
-51,040
-62% -$2.47M ﹤0.01% 2238
2022
Q3 		$3.97M Sell
82,657
-72,734
-47% -$4.33M ﹤0.01% 1510
2022
Q2 		$8.86M Buy
155,391
+89,410
+136% +$5.64M ﹤0.01% 1168
2022
Q1 		$5.33M Buy
65,981
+57,868
+713% +$8.56M ﹤0.01% 1553
2021
Q4 		$1.64M Sell
8,113
-10,348
-56% -$2.24M ﹤0.01% 2246
2021
Q3 		$4.97M Sell
18,461
-153
-0.8% -$36.8K ﹤0.01% 1611
2021
Q2 		$4.79M Sell
18,614
-266
-1% -$73.6K ﹤0.01% 1650
2021
Q1 		$5.66M Buy
18,880
+422
+2% +$131K ﹤0.01% 1487
2020
Q4 		$4.71M Sell
18,458
-366
-2% -$94.6K ﹤0.01% 1516
2020
Q3 		$4.68M Sell
18,824
-328
-2% -$103K ﹤0.01% 1373
2020
Q2 		$6.65M Sell
19,152
-1,251
-6% -$390K ﹤0.01% 1180
2020
Q1 		$5.46M Sell
20,403
-123
-0.6% -$38K ﹤0.01% 1139
2019
Q4 		$6.65M Buy
20,526
+2,559
+14% +$742K ﹤0.01% 1268
2019
Q3 		$4.91M Buy
17,967
+18
+0.1% +$6.6K ﹤0.01% 1400
2019
Q2 		$9.58M Buy
17,949
+430
+2% +$216K 0.01% 1083
2019
Q1 		$8.83M Sell
17,519
-3
-0% -$1.78K 0.01% 1107
2018
Q4 		$8.64M Buy
17,522
+398
+2% +$240K 0.01% 1043
2018
Q3 		$15.7M Sell
17,124
-89
-0.5% -$76K 0.01% 859
2018
Q2 		$12.6M Sell
17,213
-11,963
-41% -$13.8M 0.01% 884
2018
Q1 		$46.5M Buy
29,176
+11,609
+66% +$15M 0.03% 501
2017
Q4 		$15.7M Buy
17,567
+2,151
+14% +$1.27M 0.01% 843
2017
Q3 		$5.55M Hold
15,416
– – ﹤0.01% 1168
2017
Q2 		$4.52M Buy
15,416
+1,474
+11% +$426K ﹤0.01% 1268
2017
Q1 		$4.91M Sell
13,942
-887
-6% -$199K ﹤0.01% 1200
2016
Q4 		$2.73M Sell
14,829
-1,220
-8% -$248K ﹤0.01% 1616
2016
Q3 		$4.14M Hold
16,049
– – ﹤0.01% 1227
2016
Q2 		$3.43M Buy
16,049
+633
+4% +$141K ﹤0.01% 1269
2016
Q1 		$3.18M Sell
15,416
-746
-5% -$143K ﹤0.01% 1282
2015
Q4 		$4.08M Sell
16,162
-74
-0.5% -$15.2K ﹤0.01% 1146
2015
Q3 		$2.67M Sell
16,236
-17,680
-52% -$3.13M ﹤0.01% 1429
2015
Q2 		$6.36M Hold
33,916
– – 0.01% 1019
2015
Q1 		$5.6M Buy
33,916
+12,085
+55% +$2.48M ﹤0.01% 1071
2014
Q4 		$5.08M Sell
21,831
-8,663
-28% -$1.85M ﹤0.01% 1113
2014
Q3 		$5.52M Buy
30,494
+8,513
+39% +$1.63M ﹤0.01% 1050
2014
Q2 		$4.23M Sell
21,981
-5
-0% -$884 ﹤0.01% 1222
2014
Q1 		$4M Sell
21,986
-382
-2% -$75.6K ﹤0.01% 1249
2013
Q4 		$3.81M Hold
22,368
– – ﹤0.01% 1279
2013
Q3 		$3.51M Hold
22,368
– – ﹤0.01% 1290
2013
Q2 		$3.88M Buy
+22,368
New +$3.43M ﹤0.01% 1142

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein's NKTR Position: Q2 2025 in Review

AllianceBernstein sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 3,280 shares — an estimated $33.5K sold.

AllianceBernstein first reported a position in NKTR in Q2 2013 and held it in 44 quarters. The position peaked at $46.5M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • AllianceBernstein reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 3,280 Nektar Therapeutics shares in Q2 2025, an estimated $33.5K.
  • AllianceBernstein first reported a position in Nektar Therapeutics in Q2 2013 and held it in 44 quarters.
  • AllianceBernstein's Nektar Therapeutics position peaked at $46.5M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.